Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study

Koukourakis, Michael I.; Tsoutsou, Pelagia G.; Karpouzis, Anthony; Tsiarkatsi, Maria; Karapantzos, Ιlias; Daniilidis, Vassilios; Kouskoukis, Constantine E.

doi:10.1016/j.ijrobp.2009.04.060

Cited by 30 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatmentrelated toxicity was described in all three studies, but due to the lack of control subjects, no conclusion on the effect of amifostine on oral mucositis could be drawn in either study. A lower, though not significantly different, incidence of severe mucositis in patients who received doses of amifostine equal [44] IV No guideline possible Mucositis not improved with amifostine, but study neither blinded nor controlled study [31].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 91%

“…Subcutaneous administration has been tested for the prevention of oral mucositis in head and neck cancer patients, who received radiotherapy or chemoradiotherapy. A total of six articles were reviewed [18,31,[41][42][43][44].…”

Section: Subcutaneous Administrationmentioning

confidence: 99%

“…Four articles were reviewed [31,41,43,44]. The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

“…The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31]. The other three studies tested the feasibility of the use of subcutaneous amifostine [41,43,44]. One of them combined 26 patients who received chemoradiotherapy with seven patients, who received radiotherapy alone [41].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review of amifostine for the management of oral mucositis in cancer patients

Nicolatou‐Galitis

Sarri²,

Bowen

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

Purpose The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Results Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Conclusion Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment

show abstract

Section: Chemoradiotherapy: Preventionmentioning

confidence: 91%

Section: Subcutaneous Administrationmentioning

confidence: 99%

“…Four articles were reviewed [31,41,43,44]. The rate of oral mucositis was not improved with amifostine in one randomized but neither blinded nor placebo-controlled study [31].…”

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

Section: Chemoradiotherapy: Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of amifostine for the management of oral mucositis in cancer patients

Nicolatou‐Galitis

Sarri²,

Bowen

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The combination of amifostine, cetuximab, weekly cisplatin (30 mg/m2) along with conformal/hypofractionated RT (2.7 Gy/fraction, total 21 fractions in 4 weeks) was evaluated in a Greek study by Koukourakis et al (Koukourakis et al, 2010). In this study, 43 patients were treated with the dosing of amifostine individualized according to tolerance.…”

Section: Cetuximab and Chemoradiotherapymentioning

confidence: 99%

Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers

Rathore¹

2012

Head and Neck Cancer

View full text Add to dashboard Cite

A forest plot analysis was done to assess whether certain patient groups benefitted with the addition of cetuximab to RT. In this analysis, factors which were associated with a potential increased benefit included presence of oropharyngeal tumors, concomitant boost RT, early T stage (T1-T3), high Karnofsky performance score (90%-100%), male sex, and age < 65 years. These results are provocative but given that the trial was not powered for this subgroup analysis, they should be interpreted with caution.Patients who received cetuximab commonly developed an acneiform rash (83.7%); the severity of the rash was grade 3-4 in 16.8% patients. Infusion-related reactions were also seen in 15.4% patients; in 3.9% patients these were of grade 3/4 severity. However, in-field toxicities, such as mucositis, dermatitis, and dysphagia did not significantly increase with the addition of cetuximab to RT. Quality-of-life parameters were not adversely affected by the addition of cetuximab. This study allowed different RT fractionation regimens which may have impacted results and survival outcomes.

show abstract

Systemic Therapies in the Management of Head and Neck Cancer

Maksymiuk

2012

Head and Neck Cancer Clinics

View full text Add to dashboard Cite

Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study

Cited by 30 publications

References 23 publications

Systematic review of amifostine for the management of oral mucositis in cancer patients

Systematic review of amifostine for the management of oral mucositis in cancer patients

Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers

Systemic Therapies in the Management of Head and Neck Cancer

Contact Info

Product

Resources

About